When research into an experimental drug or medical procedure is called into question, the consequences can be devastating.

CMS has pushed back implementation of new surveyor guidance until March, giving regulators more time to fine-tune compliance.

Next, conflicts arise from the varying perspectives from which to present medical information to parents. Considering the principle of autonomy, experts agree disclosure of evidence-based ...